Compare Raytheon Technologies Corp (RTX) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raytheon Technologies Corp vs Summit Therapeutics Inc — how do they compare? Raytheon Technologies Corp trades at $185.97 (market cap $248.42B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Raytheon Technologies Corp is far larger — about 18.1× Summit Therapeutics Inc's market cap, and Raytheon Technologies Corp pays a 1.58% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Raytheon Technologies Corp for 77 Days and Summit Therapeutics Inc for 16 Days on average.
| RTX | SMMT | |
|---|---|---|
Market Cap | $248.42B | $13.71B |
Volume | 4,380,368 | 6,173,057 |
Sector | Industrials | Health |
52-Week High | $225.49 | $26.38 |
52-Week Low | $157.00 | $12.43 |
Typical Hold Time | 77 Days | 16 Days |
Enterprise Value | $278.97B | $13.04B |
Dividend Yield | 1.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RTX trades at $184.32, up 2.25% with strong earnings momentum as Q1 and Q2 2026 results beat expectations. The stock shows bearish technical signals but benefits from a $289 billion backlog and rising defense spending. Revenue grew to $88.6 billion in 2025 with net income of $6.73 billion, while analyst consensus remains bullish with a $236.27 price target.
Outlook is positive given defense budget tailwinds and operational execution, though technical weakness and debt levels pose risks. The company's dividend and backlog provide stability, but investors should monitor geopolitical impacts and interest rate sensitivity.
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
